NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
Conditions
Lung Cancer
Conditions: official terms
Lung Neoplasms
Conditions: Keywords
Patient diagnosed with lung cancer
Study Type
Observational [Patient Registry]
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Not yet recruiting
Summary
NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to identify functionally-impactful driver mutations regardless of whether the mutation has previously been described or linked to a tumor type.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 85 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients that are suspected to have lung cancer and are eligible for biopsy, surgical intervention or pleural fluid suction

Exclusion Criteria:

- Patients without lung cancer
Location
Rabin Medical Center, Beilinson
Petah Tikva, Israel
Status: Not yet recruiting
Start Date
October 2014
Completion Date
October 2015
Sponsors
NovellusDx
Source
NovellusDx
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page